NASDAQ:ADTX Aditxt (ADTX) Stock Price, News & Analysis $1.35 -0.03 (-2.17%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.31▼$1.4450-Day Range$1.35▼$2.3252-Week Range$1.30▼$68.08Volume183,460 shsAverage Volume455,204 shsMarket Capitalization$2.69 millionP/E RatioN/ADividend YieldN/APrice Target$61.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Aditxt alerts: Email Address Aditxt MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside4,418.5% Upside$61.00 Price TargetShort InterestBearish11.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.34Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.68 out of 5 stars 3.5 Analyst's Opinion Consensus RatingAditxt has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAditxt has received no research coverage in the past 90 days.Read more about Aditxt's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted11.06% of the float of Aditxt has been sold short.Short Interest Ratio / Days to CoverAditxt has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aditxt has recently increased by 24.15%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAditxt does not currently pay a dividend.Dividend GrowthAditxt does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADTX. Previous Next 3.0 News and Social Media Coverage News SentimentAditxt has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Aditxt this week, compared to 2 articles on an average week.Search Interest4 people have searched for ADTX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows1 people have added Aditxt to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aditxt insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.23% of the stock of Aditxt is held by insiders.Percentage Held by InstitutionsOnly 15.54% of the stock of Aditxt is held by institutions.Read more about Aditxt's insider trading history. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share RatioAditxt has a P/B Ratio of 0.02. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aditxt's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressThis TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.But I can promise that you’ll see all the details for yourself here. About Aditxt Stock (NASDAQ:ADTX)Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. It is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.Read More ADTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADTX Stock News HeadlinesJuly 25 at 11:58 AM | uk.finance.yahoo.comFCA makes first crypto-related sting against Coinbase subsidiaryJuly 25 at 9:00 AM | globenewswire.comEvofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1stJuly 26, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.July 23 at 8:47 AM | prnewswire.comEvofem Signs Phexxi® License Agreement for Middle East with Pharma 1July 19, 2024 | msn.comWhat's Going On With Aditxt Shares Wednesday?July 17, 2024 | investorplace.comWhy Is Aditxt (ADTX) Stock Up 72% Today!July 15, 2024 | prnewswire.comLupin Divests U.S. Commercial Women's Health Specialty Business to Evofem, including SOLOSECJune 27, 2024 | prnewswire.comHello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's HealthcareJuly 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! June 11, 2024 | prnewswire.comEvofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of MatterMay 15, 2024 | finanznachrichten.deEvofem Biosciences, Inc.: Evofem Biosciences Announces Financial Results for the First Quarter of 2024May 15, 2024 | prnewswire.comEvofem Biosciences Announces Financial Results for the First Quarter of 2024May 5, 2024 | investing.comAditxt secures $4.2 million in private placementMay 3, 2024 | finance.yahoo.comCORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq RulesMay 3, 2024 | businesswire.comAditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq RulesApril 2, 2024 | marketwatch.comAditxt to Buy Biopharmaceutical Company Appili Therapeutics for Undisclosed AmountApril 2, 2024 | markets.businessinsider.comAppili Therapeutics To Be Acquired By AditxtApril 2, 2024 | businesswire.comAditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)See More Headlines Receive ADTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aditxt and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/20/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADTX CUSIPN/A CIK1726711 Webwww.aditxt.com Phone650-870-1200FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$61.00 High Stock Price Target$61.00 Low Stock Price Target$61.00 Potential Upside/Downside+4,418.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,380,000.00 Net Margins-5,016.31% Pretax Margin-9,654.42% Return on Equity-927.61% Return on Assets-186.82% Debt Debt-to-Equity RatioN/A Current Ratio0.09 Quick Ratio0.06 Sales & Book Value Annual Sales$640,000.00 Price / Sales4.20 Cash FlowN/A Price / Cash FlowN/A Book Value$67.18 per share Price / Book0.02Miscellaneous Outstanding Shares1,990,000Free Float1,969,000Market Cap$2.69 million OptionableNo Data Beta1.24 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Amro A. Albanna (Age 54)Co-Founder, Chairman & CEO Comp: $472.12kDr. Shahrokh Shabahang D.D.S. (Age 61)M.S., Ph.D., Co-Founder, Chief Innovation Officer, Secretary & Director Comp: $323.5kMr. Thomas J. Farley CPA (Age 51)Chief Financial Officer Comp: $357.89kMs. Corinne D. Pankovcin CPA (Age 58)M.B.A., Chief Commercialization Officer Comp: $366.77kMs. Rowena Albanna (Age 58)Chief Operating Officer Ms. Jennifer LeeDirector of Human ResourcesDr. Dolly B. Tyan Ph.D.Senior Vice President of Clinical Development TransplantationMr. Ge Chen M.D.M.S., Senior Vice President of Preclinical Research & DiscoveryMore ExecutivesKey CompetitorsImunonNASDAQ:IMNNCardio DiagnosticsNASDAQ:CDIOEterna TherapeuticsNASDAQ:ERNAPHAXIAM TherapeuticsNASDAQ:PHXMRedHill BiopharmaNASDAQ:RDHLView All CompetitorsInsidersParibas Securities Corp BnpSold 20,800 sharesTotal: $691,184.00 ($33.23/share)View All Insider Transactions ADTX Stock Analysis - Frequently Asked Questions How have ADTX shares performed this year? Aditxt's stock was trading at $6.63 on January 1st, 2024. Since then, ADTX shares have decreased by 79.6% and is now trading at $1.35. View the best growth stocks for 2024 here. How were Aditxt's earnings last quarter? Aditxt, Inc. (NASDAQ:ADTX) issued its quarterly earnings results on Monday, May, 20th. The company reported ($9.14) earnings per share for the quarter, missing the consensus estimate of ($3.33) by $5.81. Aditxt had a negative net margin of 5,016.31% and a negative trailing twelve-month return on equity of 927.61%. When did Aditxt's stock split? Aditxt shares reverse split on Friday, August 18th 2023. The 1-40 reverse split was announced on Friday, August 18th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are Aditxt's major shareholders? Aditxt's top institutional investors include Concourse Financial Group Securities Inc.. Insiders that own company stock include Paribas Securities Corp Bnp and Amro A Albanna. View institutional ownership trends. How do I buy shares of Aditxt? Shares of ADTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Aditxt own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aditxt investors own include Tesla (TSLA), Dynavax Technologies (DVAX), Boeing (BA), CrowdStrike (CRWD), Genius Brands International (GNUS), Nikola (NKLA) and Block (SQ). This page (NASDAQ:ADTX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aditxt, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aditxt With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
